FIU Discovery

Article

• 2018

  Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.  New England Journal of Medicine.  379:645-654.

  Full Text via DOI: 10.1056/NEJMoa1711460 Web of Science: 000441659100008